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Introduction. The microbial biofilm-forming ability is one of the major aspects of the emerg-
ing issue of antibiotic resistance, which makes them tolerant to antibiotics and host defense 
systems and other external stresses, thus contributing to persistent chronic infect ions. A series 
of relevant studies confirmed the high efficiency of aminopropanol derivatives as potential 
antibacterial and antifungal agents. This present study was aimed to evaluate the antimicro-
bial activity of new 1-[(2,4-(di-tert-butylphenoxy))-3-dialkylamino-2-propanol] derivatives 
on the planktonic bacterial/fungal cells and biofilms.  
Material and methods. The minimum inhibitory concentrations (MIC) of the new compounds 
were determined by a standard method, along with their effects on biofilms estimated via the 
gentian violet adsorption-desorption assay. 
Results. The КVM-219 compound showed the most pronounced effect on planktonic bacterial 
and fungal cells. The MIC values ranged between 0.78 μg/mL to 12.5 μg/mL, depending on the 
microbial strain. The KVM-316 compound exhibited the strongest inhibitory effect on biofilms, 
thus preventing their formation by S. aureus (96.1%), E. coli (57.2%), and P. aeruginosa 
(96.1%).   
Conclusions. The 15 newly synthesized 1-[(2,4-(di-tert-butylphenoxy))-3-dialkylamino-2-
propanol] derivatives revealed marked antibacterial and antifungal effects on planktonic mi-
croorganisms. Most of these compounds showed a strain-specific inhibition of biofilm for-









ACTIVITATEA ANTIMICROBIANĂ A NOILOR DERIVAȚI DE 1 - [(2,4-(DI-TERT-
BUTYLPHENOXY)) - 3-DIALKILAMINO-2-PROPANOL] 
Introducere. Scopul studiului l-a constituit evaluarea efectelor antimicrobiene ale derivaților 
1 - [(2,4 (di-terț- butylphenoxy)) - 3- dialkylamino-2-propanol] asupra celulelor planctonice 
bacteriene/fungice și asupra biofilmelor. 
Material și metode. Concentrațiile minime inhibitorii (CMI) ale compușilor noi au fost deter-
minate printr-o metodă standard, activitatea antibiofilm a fost testată prin absorbția violetu-
lui de gențiană pe structuri formate pe plăci de polistiren, urmată de resolubilizare cu solvent 
organic și resazurină ca indicator redox. 
Rezultate. Efectul cel mai pronunțat asupra celulelor planctonice bacteriene și fungice l-a 
demonstrat compusul КVM -219, CMI 0,67 μg/ml - 12,5 μg/ml, în funcție de microorganism, 
iar asupra biofilmelor - compusul KVM-316. KVM-316 a prevenit formarea biofilmelor de 
către S. aureus (96,1%), E. coli (57,2%) și P. aeruginosa (96,1%).  
Concluzii. Cei 15 derivați nou sintetizați ai 1 - [(2,4- (di- tert-butylphenoxy)) - 3- dialkylamino 
-2-propanol] au prezentat efecte antibacteriene și antifungice pronunțate asupra microorga-
nismelor planctonice. Majoritatea acestor compuși au inhibat în mod specific formarea bio-
filmelor de către tulpinile clinice S. aureus 222, E. coli 311, P. aeruginosa 449 și C. glabrata 
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Over the decades, antimicrobial agents have been 
considered the primary suppressing means for 
bacterial infections. However, their irrational use 
led to the emergence and spread of antimicrobial-
resistant strains (1, 2). The antimicrobial drug re-
sistance has led to a decrease of infection preven-
tion and control measures and lowered the ther-
apeutic effectiveness thus resulting in a pro-
longed patient’s hospital stay and increased treat-
ment costs. The antibiotic resistance has been re-
garded nowadays as a major threat to public in-
ternal safety across many countries. Therefore, a 
global action plan to overcome antimicrobial re-
sistance has been developed by World Health As-
sembly (3). In 2017, WHO presented a list of 12 
bacterial species that pose a threat to human 
health, which are classified into three categories 
of pathogens, namely critical, high and medium 
priority, according to the urgency of need for new 
antibiotics (4). The goal of the global action plan 
is to ensure, for as long as possible, continuity of 
successful treatment and prevention of infectious 
diseases by effective and safe medicines that are 
quality-assured, used in a responsible way and ac-
cessible to all who need them.  To achieve this 
goal, five strategic objectives have been set out: to 
improve awareness and understanding of antimi-
crobial resistance; to strengthen knowledge 
through surveillance and research; to reduce the 
incidence of infection; to optimize the use of anti-
microbial agents; to develop the economic case 
for sustainable investment that takes account of 
the needs of all countries; and to increase invest-
ments in new medicines, diagnostic tools, vac-
cines and other interventions (3). Considering all 
of the above mentioned, the most promising ap-
proach is to search for potentially novel antimi-
crobial agents for combatting antimicrobial re-
sistance. 
The microbial biofilm-forming ability is one of the 
major aspects of the emerging issue of antibiotic 
resistance, which makes them tolerant to antibi-
otics and host defence systems and other external 
stresses, thus contributing to persistent chronic 
infections (5).  Several studies confirmed the high 
efficiency of aminopropanol derivatives as poten-
tial antibacterial and antifungal agents, which ac-
tually drew our interest to compounds of this 
group (6, 7, 8). 
The purpose of the present study was to evaluate 




MATERIAL AND METHODS  
Bacterial strain and growth conditions 
The study was conducted on the gram-positive 
(Staphylococcus aureus subsp. aureus (ATCC® 
25923TM), S. aureus 222 (MRSA)) and gram-nega-
tive (Escherichia coli (ATCC® 25922TM), E. coli 
311, Pseudomonas aeruginosa (ATCC® 27853 TM), 
P. aeruginosa 449) bacterial strains, and yeasts 
(Candida albicans NTCC 885/653, C. glabrata 
404). The bacterial strains were subcultured at 
37°С in Mueller-Hinton broth (HiMedia™ Labora-
tories Pvt Ltd) and Tryptic Soy Broth (TSB) 
(Merck Millipore) (pH 7.3), yeasts – at 30-32°С in 
Saburo dextrose broth (HiMedia™ Laboratories 
Pvt Ltd) (pH 5.6). 
Chemicals 
The new derivatives of 1-[(2,4-(di-tert-butylphe-
noxy))-3-dialkylamino-2-propanol] were first 
synthesised at the Institute of Organic Chemistry 
NAS of Ukraine. These compounds were synthe-
sized by using the same procedure (9). Its general 
structural formula is shown in Figure 1. 
 
 
R1 – (2,4-di-tert-butylphenyl); R2,R3 – alkyl, dialkyl, cycloalkyl; R4 − methyl, benzyl, 4-nitrobenzyl, 4-
metoxybenzyl, 4-сhlorobenzyl, 4- fluorobenzyl, 4-methylbenzyl; Hal – Cl-, (I-). 
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Minimum Inhibitory Concentration (MIC) de-
termination 
Synthesized compounds antimicrobial activity (I 
– XV) was tested by the twofold serial dilution 
method (10, 11) against gram-positive (S. aureus 
ATCC 25923) and gram-negative (E. coli ATCC 
25922, P. aeruginosa ATCC 27853) bacteria, and 
yeasts (C. albicans NTCC 885/653). Inoculum 
density was 1-2×105 CFU/mL culture medium 
(bacteria) and 1-2×104 CFU/mL (yeasts). The 96-
well microtiter plates with bacterial cultures 
were incubated at 35-37°C for 18-24 h, while 
yeasts – at 30-32oС for 24-48 h. Mueller-Hinton 
broth and Saburo dextrose broth were used for 
minimal inhibitory concentration (MIC) determi-
nation. The lowest compound concentration in-
hibiting the microbial growth was considered as 
the MIC. All assays were performed in triplicate 
for control of culture growth (as a positive) and 
cultural media (as a negative). 
Quantitative biofilm assay 
The anti-biofilm activity of the tested compounds 
was determined by using the microtiter plate for 
biofilm formation assay described by O’Toole 
(12). The overnight cultures were diluted 100-
fold with fresh TSB medium (bacteria) or Saburo 
dextrose broth (yeasts). Cell suspensions (100 
µL) were transferred into individual wells of ster-
ile polystyrene 96-well plate. The anti-biofilm ef-
fect was estimated by growing strains in media 
with or without test compounds (2.0×MIC) at 
37oC for 24 hours. After incubation, the media 
were discarded, and plates were rinsed thrice 
with distillate water to remove nonadherent cells. 
Adherent cells were stained for 10-15 min with 
0.1% crystal violet. The dye was extracted with 
ethanol for 15 min to quantify biofilm formation. 
The optical density was measured at 630 nm via 
the Absorbance Microplate Reader (model 
ELx800, BioTek, USA). The measurements were 
performed in six replications and repeated for at 
least three times; the values were then averaged.  
Statistical Analysis 
Newman-Keils (ANOVA) and Kruskal-Wallis cri-
teria were used to assess the results via the STA-
TISTICA, version 6.0 (StatSoft. Inc., USA) (13). 
Data are presented as M±m, where M is the mean 
value and m is the standard error of the mean. 
 
RESULTS  
The studies of antibacterial and antifungal activi-
ties confirmed that 1-[(2,4-(di-tert-butylphe-
noxy))-3-dialkylamino-2-propanol] new deriva-
tives caused inhibitory effect on S. aureus and C. 
albicans, with the MIC values ranging from 0.78 to 
3.75 μg/mL and from 1.56 to 20.0 μg/mL, respec-
tively. These compounds revealed no antibacte-
rial effects against gram-negative bacteria, except 
for the VII and IV compounds, the МІС value for E. 
coli reaching to 12.5 μg/mL and 20.0 μg/mL, re-
spectively (tab. 1, 2). 
 




S. aureus subsp. au-
reus  
(ATCC® 25923TM)  




C. albicans NTCC 
885/653 
КVM-190 (I) 2.5 >20.0 >20.0 3.75 
КVM-266 (II) 5.0 >20.0 >20.0 7.5 
КVM-267 (III) 5.0 >20.0 >20.0 7.5 
КVM-316 (IV) 5.0 20.0 >20.0 5.0 
КVM-251 (V) 3.12 >20.0 >20.0 12.5 
КVM-327 (VI) 1.56 >20.0 >20.0 6.25 
КVM-219 (VII) 0.78 12.5 >20.0 1.56 
КVM-220 (VIII) 2.5 >20.0 >20.0 3.75 
КVM-269 (IX) 5.0 >20.0 >20.0 7.5 
КVM-268 (X) 5.0 >20.0 >20.0 7.5 
КVM-221 (XI) 7.5 >20.0 >20.0 5.0 
КVM-222 (XII) 3.75 >20.0 >20.0 2.5 
КVM-319 (XIII) 1.56 >20.0 >20.0 20.0 
КVM-317 (XIV) 5.0 >20.0 >20.0 5.0 
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Table 2. Structure of 1-[(2,4-(di-tert-butylphenoxy))-3-dialkylamino-2-propanol] derivatives in corre-




Substituents МІC, μg/mL 
R1 R2 R3 R4 Hal S. aureus C. albicans 
І 2,4-[(CH3)3C]С6Н3 CH3 CH3 CH2C6H5 Cl- 2.5 3.75 
ІІ 2,4-[(CH3)3C]С6Н3 CH3 CH3 СН2(С6Н4)-4-NO2 Cl- 5.0 7.5 
ІІІ 2,4-[(CH3)3C]С6Н3 CH3 CH3 СН2(С6Н4)-4-
OCH3 
Cl- 5.0 7.5 
IV 2,4-[(CH3)3C]С6Н3 CH3 CH3 СН2(С6Н4)-4-Cl Cl- 5.0 5.0 
V 2,4-[(CH3)3C]С6Н3 CH3 C6H11 CH2C6H5 Cl- 3.12 12.5 
VІ 2,4-[(CH3)3C]С6Н3 CH3 C6H11 СН2(С6Н4)-4-Cl Cl- 1.56 6.25 
VІІ 2,4-[(CH3)3C]С6Н3 (C4H8) CH3 I- 0.78 1.56 
VІІІ 2,4-[(CH3)3C]С6Н3 (C4H8) CH2C6H5 Cl- 2.5 3.75 
ІХ 2,4-[(CH3)3C]С6Н3 (C4H8) СН2(С6Н4)-4-NO2 Cl- 5.0 7.5 
Х 2,4-[(CH3)3C]С6Н3 (C4H8) СН2(С6Н4)-4-
OCH3 
Cl- 5.0 7.5 
ХІ 2,4-[(CH3)3C]С6Н3 (C6H12) CH3 I- 7.5 5.0 
ХІІ 2,4-[(CH3)3C]С6Н3 (C6H12) CH2C6H5 Cl- 3.75 2.5 
ХІІІ 2,4-[(CH3)3C]С6Н3 [(СН2)2CHCH3(CH2)2] СН2(С6Н4)-4-NO2 Cl- 1.56 20.0 
ХIV 2,4-[(CH3)3C]С6Н3 [(СН2)2CHCH3(CH2)2] СН2(С6Н4)-4-CH3 Cl- 5.0 5.0 
ХV 2,4-[(CH3)3C]С6Н3 [(СН2)2CHCH3(CH2)2] СН2(С6Н4)-4-F Cl- 1.56 5.0 
 2,4-[(CH3)3C]С6Н3 –- 2,4-di-tert-butylphenyl radical. 
 
The most pronounced effect was found in the VII 
compound. The MIC value against S. aureus was 
0.78 μg/mL, E. coli − 12.5 μg/mL, and for C. albi-
cans − 1.56 μg/mL. 
Considering that biofilms are the main mode of 
microbial existence, the evaluation of their sus-
ceptibility to the tested compounds was of great 
scientific interest. Our clinical trials tested the 
following microbial strains: S. aureus 222, E. coli 
311, P. aeruginosa 449, and C. glabrata 404.  
The obtained results demonstrated that all the 
tested compounds, except for the ХІІІ compound, 
prevented S. aureus biofilm formation. The use of 
2.0×MIC decreased the mass of MRSA 222 biofilm 
by 82.5% up to 100 % compared to the untreated 
culture (tab. 3). 
 




















КVM-190 (І) 17.5±1.1* 36.1±0.8* 249.1±15.1* 261.3±6.6* 
КVM-266 (ІІ) 0.2±0.1* 31.6±5.4* 150.3±6.1* 119.5±6.6 
КVM-267 (ІІІ) 0.7±0,4* 85.9±0,5* 129.9±3.1* 160.0±43.8* 
КVM-316 (IV) 12.7±0.2* 42.8±2.1* 3.9±0.2* 83.2±2.6 
КVM-251 (V) 1.2±0.2* 127.8±1.7* 164.1±9.6* 251.3±1.5* 
КVM-327 (VІ) 0.3±0.2* 77.6±1.7* 61.1±4.3* 3.0±2.4* 
КVM-219 (VІІ) 88.8±1.5 88.0±1.5 37.2±0.2* 111.8±0.0 
КVM-220 (VІІІ) 0.2±0.2* 77.7±0.4* 174.9±3.7* 77.5±2.5 
КVM-269 (ІХ) 0.2±0.1* 91.1±1.7* 69.7±3.3* 9.6±1.9* 
КVM-268 (Х) 0.1±0,0* 92.8±0.4 145.5±1.6* 3.8±1.9* 
КVM-221 (ХІ) 12.4±4.0* 111.4±0.7* 145.5±3.2* 187.5±7.5* 
КVM-222 (ХІІ) 0.0±0.0* 98.1±1.6 131.1±3.2* 161.9±13.0* 
КVM-319 (ХІІІ) 51.4±2.9* 93.7±1.1 106.2±3.1 17.3±3.3* 
КVM-317 (ХIV) 0.6±0.6* 106.9±1.8* 63.0±4.9* 1.3±0.9* 
КVM-318 (XV) 0.4±0.3* 96.3±0.1 79.1±1.7* 11.5±5.1* 
*р<0.05 in comparison with control. 
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At the same time E. coli biofilms were less suscep-
tible to 1-[(2,4-(di-tert-butylphenoxy))-3-dialkyl-
amino-2-propanol] derivatives. Among all tested 
derivatives, the І, ІІ and IV compounds showed 
the most pronounced inhibitory effects (63.9%, 
68.4% and 57.2%, respectively, p<0.05). 
The 1-[(2,4-(di-tert-butylphenoxy))-3-dialkyla-
mino-2-propanol] derivatives almost did not in-
hibit P. aeruginosa biofilm formation. Only two 
compounds, namely the IV (96.1%) and VІІ 
(62.8%) exhibited the most pronounced inhibi-
tory effect, whereas the VІ (38.9%), ІХ (30.3%), 
ХIV (37.0%) and XV (20.9%) derivatives showed 
a lesser activity. Unlike these ones, the І, ІІ, ІІІ, V, 
VІІІ, Х, ХІ, ХІІ, and ХІІІ compounds even stimu-
lated the P. aeruginosa biofilm formation. 
Thus, according to the study results the most pro-
nounced inhibitory effect on biofilms formation 
were found for the IV compound, with a 96.1% 
decrease in S. aureus biofilm mass, 57.2% − E. coli 
and 96.1% − P. aeruginosa. 
As regarding the C. glabrata biofilm formation, a 
pronounced inhibitory effect was demonstrated 
by the VІ, ІХ, Х, ХІІІ, ХIV and XV compounds 
(82.7%-98.7% biofilm mass decrease).  
 
DISCUSSIONS 
The comparative study of the antibacterial and 
antifungal activity of 1-[(2,4-(di-tert-buty-lphe-
noxy))-3-dialkylamino-2-propanol] derivatives 
with various substituents in the molecular struc-
ture showed that substitutes close to the amino 
fragment might affect the antimicrobial activity of 
the tested compounds (tab. 2). 
By introducing the N-benzyl dimethylamine (I); 
N-benzyl pyrrolidine (VIII) and N-benzyl hexa-
methyleneamine (XII) groups to the structure of 
1-[(2,4-(di-tert-butylphenoxy))-3-dialkylamino-
2-propanol] at the amino fragment, an inhibitory 
effect towards S. aureus and C. albicans ranging 
between 2.5-3.75 μg/mL was registered. 
The addition of the substituents on the benzylic 
radical in the 4-position, namely the nitro group 
(II, IX), methoxy group (III and X) and chlorine 
group (IV) exhibited an increased inhibitory ac-
tivity of 1-[(2,4-(di-tert-butylphenoxy))-3-dial-
kylamino-2-propanol] derivatives. Their MIC val-
ues for S. aureus and C. albicans ranged between 
5.0-7.5 μg/mL. 
Another heterocyclic substituent (4-methylpiper-
idine) inserted to the 1-[(2,4-(di-tert-butylphe-
noxy))-3-dialkylamino-2-propanol] molecular 
derivatives, viz. XIV and XV, did not significantly 
affect their antifungal activities compared with II 
compound. At the same time, the antibacterial ac-
tivity of XV compound (MIC 1.56 μg/mL) towards 
S. aureus increased, compared to the II compound 
(MIC 5.0 μg/mL).  
Upon the insertion of a nitro group at the 4-posi-
tion to the benzylic radical, viz. the XIII com-
pound, it showed a reduced antifungal activity 
(MIC 20.0 μg/mL) in comparison with XII com-
pound (2.5 μg/mL). 
The replacement of one of the methyl groups for 
cyclohexyl in the molecule of the V compound led 
to a decrease of its antifungal activity (MIC 12.5 
μg/mL), while its inhibitory effect towards S. au-
reus remained nearly unchanged (MIC 3.12 
μg/mL) compared with the I compound (MIC 2.5 
μg/mL).  
The introduction of the chlorine at the 4-position 
led to completely different consequences: the MIC 
value of the VІ compound showed a two-fold de-
crease in comparison with the MIC values of the I 
and V compounds (S. aureus − 1.56-3.12 μg/mL; 
C. albicans − 25.0-12.5 μg/mL). However, this de-
crease was not statistically significant.  
The addition of N-methylpyrrolidine fragment to 
the amino group allowed to increase the antibac-
terial and antifungal activity of the VII derivative 
by 3.2 and 2.4 times, respectively (compared with 
I and VIII compounds). The MIC values towards S. 
aureus and C. albicans decreased to 0.78 μg/mL 
and 1.56 μg/mL, respectively.  
The replacement of hexamethylenamine pyrroli-
dine radical in the XI derivative was accompanied 
by a decreased inhibitory activity (compared to 
the VII compound), whereas the MIC values to-
wards S. aureus and C. albicans were 5.0-7.5 
μg/mL.  
This present study demonstrated that both tested 
derivatives 1-[(2,4-(di-tert-butylphenoxy))-3-di-
alkylamino-2-propanol] were able to suppress 
the gram-positive and gram-negative bacteria in 
fungal (C. glabrata) planktonic microorganisms 
and biofilms formation processes. The compara-
tive structure-activity analysis showed that the 
inhibitory effect depended not only on the molec-
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2-propanol] derivatives, but also on the microbial 
strain used. 
Thus, the trials carried out on planktonic and bio 
film cultures demonstrated that the newly syn-
thesized derivatives of 1-[(2,4-(di-tert-butylphe-
noxy))-3-dialkylamino-2-propanol] exhibited an 
inhibitory effect against bacteria and fungi. 
 
CONCLUSIONS 
1. The studies on planktonic microorganisms demonstrated that the newly synthesized derivatives 
of 1-[(2,4-(di-tert-butylphenoxy))-3-dialkylamino-2-propanol] have antibacterial and antifun-
gal effects. This research showed that the anti-biofilm effects of the most evaluated compounds 
could specifically reduce the biofilm formation ability of S. aureus 222, E. coli 311, P. aeruginosa 
449 and C. glabrata 404 by at least 50%, depending on the nature of the substituents used in 
their molecules. 
2. The newly synthesized derivatives of 1-[(2,4-(di-tert-butylphenoxy))-3-dialkylamino-2-propa-
nol] represent a promising class of chemical compounds, which might lead to the development 
of novel antimicrobial agents intended for the treatment of many infectious diseases. Further 
researches are required to study the broad activity spectrum of compounds with the most pro-
nounced antimicrobial action, as well as their antibacterial and antifungal mechanisms, acute 
toxicity and efficacy in vivo. 
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